Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening

(Chemical Equation Presented) We first identified fluorescein, ketazolam, antrafenine, darifenacin, fosaprepitant, paliperidone, risperidone, pimozide, trovafloxacin, and levofloxacin as inhibitors of fatty acid binding protein 4 using molecular docking screening from FDA-approved drugs. Subsequently, the biochemical characterizations showed that levofloxacin directly inhibited FABP4 activity in both the in vitro ligand displacement assay and cell-based function assay. Furthermore, levo floxacin did not induce adipogenesis in adipocytes, which is the major adverse effect of FABP4 inhibitors.